Literature DB >> 21825992

Compositional differences among commercially available botulinum toxin type A.

Erez Bakshi1, Morris E Hartstein.   

Abstract

PURPOSE OF REVIEW: Since the advent of botulinum neurotoxin (BoNT) in the facial cosmetic field, it has become the leading nonsurgical cosmetic procedure in the USA, and several different formulations are currently in use. The aim of this study is to review the major 'players' in order to help the physician understand the clinically relevant dissimilarities between the products and by that promote treatment efficacy and patient satisfaction. RECENT
FINDINGS: The different available formulations can be classified into two groups by the existence of absence of complexing proteins. Most of the influence that was previously attributed to these proteins has been found to be less relevant clinically, the immune response being the only remaining issue with supporting evidence in the literature.
SUMMARY: Botulinum toxin type A is widely utilized in the cosmetic field, and it seems that all available and approved formulations are both well tolerated and effective in treating facial rhytids. The treating physician must be familiar with the differences between all the products, especially the fact that they are not interchangeable in respect to their recommended dosage.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21825992     DOI: 10.1097/ICU.0b013e328349b0b6

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  1 in total

1.  Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.

Authors:  Welf Prager
Journal:  Clin Pharmacol       Date:  2013-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.